These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 25299626)

  • 21. Medication discontinuation with depot and oral antipsychotics in outpatients with schizophrenia: comparison of matched cohorts from a 12-month observational study.
    Brnabic AJ; Kelin K; Ascher-Svanum H; Montgomery W; Kadziola Z; Karagianis J
    Int J Clin Pract; 2011 Sep; 65(9):945-53. PubMed ID: 21849009
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-acting injectable antipsychotics in the treatment of schizophrenia: their role in relapse prevention.
    Agid O; Foussias G; Remington G
    Expert Opin Pharmacother; 2010 Oct; 11(14):2301-17. PubMed ID: 20586707
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Should long-acting (depot) antipsychotics be used in early schizophrenia? A systematic review.
    Taylor M; Ng KY
    Aust N Z J Psychiatry; 2013 Jul; 47(7):624-30. PubMed ID: 23209308
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Time to discontinuation of depot and oral first-generation antipsychotics in the usual care of schizophrenia.
    Zhu B; Ascher-Svanum H; Shi L; Faries D; Montgomery W; Marder SR
    Psychiatr Serv; 2008 Mar; 59(3):315-7. PubMed ID: 18308914
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
    Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
    Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Intervals between hospitalisations in schizophrenia patients under antipsychotics in depot-form versus oral second generation antipsychotics].
    Gutwinski S; Müller P; Koller M
    Psychiatr Prax; 2007 Sep; 34(6):289-91. PubMed ID: 17806015
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oral antipsychotic update: a brief review of new and investigational agents for the treatment of schizophrenia.
    Citrome L
    CNS Spectr; 2012 Nov; 17 Suppl 1():1-9. PubMed ID: 23448847
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness of community treatment orders for treatment of schizophrenia with oral or depot antipsychotic medication: clinical outcomes.
    Muirhead D; Harvey C; Ingram G
    Aust N Z J Psychiatry; 2006; 40(6-7):596-605. PubMed ID: 16756586
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of second-generation long-acting injections in schizophrenia: a meta-analysis of randomized-controlled trials.
    Fusar-Poli P; Kempton MJ; Rosenheck RA
    Int Clin Psychopharmacol; 2013 Mar; 28(2):57-66. PubMed ID: 23165366
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relapse prevention and recovery in the treatment of schizophrenia.
    Schooler NR
    J Clin Psychiatry; 2006; 67 Suppl 5():19-23. PubMed ID: 16822093
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The natural course of schizophrenia and effective maintenance drug treatment.
    Davis JM; Andriukaitis S
    J Clin Psychopharmacol; 1986 Feb; 6(1 Suppl):2S-10S. PubMed ID: 2870087
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The safety, efficacy and tolerability of Abilify Maintena for the treatment of schizophrenia.
    Kahn RS; Giannopoulou A
    Expert Rev Neurother; 2015; 15(9):969-81. PubMed ID: 26289486
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ten year outcomes of outpatients with schizophrenia on conventional depot antipsychotics: a systematic chart review.
    Uchida T; Suzuki T; Sakurai H; Tsutsumi C; Den R; Mimura M; Uchida H
    Int Clin Psychopharmacol; 2013 Sep; 28(5):261-6. PubMed ID: 23820334
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The case for long-acting antipsychotic agents in the post-CATIE era.
    Nasrallah HA
    Acta Psychiatr Scand; 2007 Apr; 115(4):260-7. PubMed ID: 17355516
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dose response of prophylactic antipsychotics.
    Davis JM; Kane JM; Marder SR; Brauzer B; Gierl B; Schooler N; Casey DE; Hassan M
    J Clin Psychiatry; 1993 Mar; 54 Suppl():24-30. PubMed ID: 8097195
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical benefits and impact of early use of long-acting injectable antipsychotics for schizophrenia.
    Stevens GL; Dawson G; Zummo J
    Early Interv Psychiatry; 2016 Oct; 10(5):365-77. PubMed ID: 26403538
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relapse and therapeutic interventions in a 1-year observational cohort study of nonadherent outpatients with schizophrenia.
    Ciudad A; San L; Bernardo M; Olivares JM; Polavieja P; Valladares A; Gilaberte I
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Mar; 36(2):245-50. PubMed ID: 22056291
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness of long-acting injectable risperidone versus oral antipsychotics in the treatment of recent-onset schizophrenia: a case-control study.
    Barrio P; Batalla A; Castellví P; Hidalgo D; García M; Ortiz A; Grande I; Pons A; Parellada E
    Int Clin Psychopharmacol; 2013 Jul; 28(4):164-70. PubMed ID: 23587986
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimizing outcomes in schizophrenia: long-acting depots and long-term treatment.
    Morrissette DA; Stahl SM
    CNS Spectr; 2012 Nov; 17 Suppl 1():10-21. PubMed ID: 23462201
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.